Skip to main content
رجوع
BIOGY logo

BioGaia AB (publ)

جودة البيانات: 100%
ذروة شراء
BIOGY
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 11.00
▼ KWD 1.21 (-11.00%)
القيمة السوقية: 1.08B
نطاق اليوم
KWD 11.00 KWD 11.00
نطاق 52 أسبوعًا
KWD 8.79 KWD 11.46
حجم التداول
1,000
متوسط 50 يوم / 200 يوم
KWD 10.75 / KWD 10.17
الإغلاق السابق
KWD 11.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 3.3 0.4
P/B 0.8 2.9
ROE % 21.9 3.7
Net Margin % 21.6 3.9
Rev Growth 5Y % 18.3 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.000
KWD 0.000 – KWD 0.000
 1.8 B 0
FY2026 KWD 0.000
KWD 0.000 – KWD 0.000
 1.6 B 0

النقاط الرئيسية

Revenue grew 18.31% annually over 5 years — strong growth
ROE of 21.91% indicates high profitability
Net margin of 21.63% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 302.97M in free cash flow
P/E of 3.26 — trading at a low valuation

النمو

Revenue Growth (5Y)
18.31%
Revenue (1Y)8.11%
Earnings (1Y)-5.30%
FCF Growth (3Y)-10.38%

الجودة

Return on Equity
21.91%
ROIC23.54%
Net Margin21.63%
Op. Margin26.82%

الأمان

Debt / Equity
0.00
Current Ratio6.12
Interest Coverage48.84

التقييم

P/E Ratio
3.26
P/B Ratio0.82
EV/EBITDA0.68
Dividend Yield0.07%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.11% Revenue Growth (3Y) 8.92%
Earnings Growth (1Y) -5.30% Earnings Growth (3Y) -4.56%
Revenue Growth (5Y) 18.31% Earnings Growth (5Y) 14.11%
Profitability
Revenue (TTM) 1.54B Net Income (TTM) 332.76M
ROE 21.91% ROA 20.83%
Gross Margin 73.37% Operating Margin 26.82%
Net Margin 21.63% Free Cash Flow (TTM) 302.97M
ROIC 23.54% FCF Growth (3Y) -10.38%
Safety
Debt / Equity 0.00 Current Ratio 6.12
Interest Coverage 48.84 Dividend Yield 0.07%
Valuation
P/E Ratio 3.26 P/B Ratio 0.82
P/S Ratio 0.70 PEG Ratio -5.65
EV/EBITDA 0.68 Dividend Yield 0.07%
Market Cap 1.08B Enterprise Value 282.16M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.54B 1.42B 1.30B 1.10B 785.11M
Net Income 332.76M 351.39M 365.35M 373.77M 196.27M
EPS (Diluted) 3.29 3.48 3.62 3.70 1.94
Gross Profit 1.13B 1.03B 950.19M 801.93M 582.95M
Operating Income 412.47M 423.37M 443.10M 361.46M 253.74M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.60B 2.03B 2.33B 2.21B 2.13B
Total Liabilities 283.59M 310.07M 302.85M 241.55M 250.69M
Shareholders' Equity 1.31B 1.72B 2.03B 1.97B 1.88B
Total Debt 0.0 29.48M 8.80M 20.09M 10.40M
Cash & Equivalents 801.31M 1.22B 1.54B 1.49B 1.48B
Current Assets 1.22B 1.61B 1.87B 1.80B 1.75B
Current Liabilities 199.14M 206.20M 195.74M 164.99M 126.95M

درجات الاستراتيجيات

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#897 of 1024
25
Custom Capital Light Compounder
#155 of 213
30
Custom Deep Value Investing (Seth Klarman)
#762 of 820
14
Growth Price/Sales Ratio Focus (Ken Fisher)
#417 of 616
24
Custom Contrarian Investing (David Dreman)
#265 of 658
36
Value Defensive Investing (Benjamin Graham)
#274 of 708
34
Value Value Investing (Warren Buffett)
#167 of 195
28

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Capital Light Compounder
Mar 24, 2026
دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026
دخل Value Investing (Warren Buffett)
Mar 24, 2026